DZD9008 is primarily used in the field of oncology as a targeted therapy for certain types of cancer. It functions as an inhibitor of specific mutations in the EGFR (epidermal growth factor receptor) gene, particularly those that are resistant to traditional treatments. This makes it a promising option for patients with non-small cell lung cancer (NSCLC) who have developed resistance to first-line EGFR inhibitors. By blocking the signaling pathways that promote cancer cell growth, DZD9008 helps to slow tumor progression and improve patient outcomes. Its application is currently under investigation in clinical trials to determine its efficacy and safety in treating advanced or metastatic cancers with specific genetic alterations.